Core Insights - China has successfully conducted its first prospective clinical trial of an invasive brain-computer interface (BCI), marking the country as the second globally to enter the clinical trial phase for this technology [1][3]. Industry Developments - The clinical trial was a collaboration between the Chinese Academy of Sciences' Center for Excellence in Brain Science and Intelligent Technology, Fudan University Huashan Hospital, and relevant enterprises [3]. - The trial involved a male subject who lost his limbs due to a high-voltage accident. Since the implantation of the BCI device in March 2025, the system has operated stably, allowing the subject to perform tasks like playing chess and racing games after 2-3 weeks of training [3]. - The BCI technology aims to improve the quality of life for patients with spinal cord injuries and amputations through motor function replacement technology [3]. Market Response - Following the announcement, stocks related to brain-computer interface technology saw significant increases, with companies like Beiyikang and Aipeng Medical reaching 30% and 20% gains, respectively [1][2]. - The Hong Kong stock market also showed strong performance in BCI-related stocks, with Nanjing Panda Electronics rising over 40% [1]. Regulatory Environment - Multiple government departments, including the National Medical Products Administration and the National Healthcare Security Administration, have introduced policies to encourage the development of BCI technology and accelerate clinical applications [3]. - In February, the National Medical Products Administration approved a project to revise industry standards for medical devices using BCI technology [3]. Future Outlook - According to Shanghai Securities research, the BCI technology is rapidly transitioning from laboratory to commercial application, indicating significant growth potential in the Chinese market [4]. - The BCI industry is suitable for medium to long-term investment, with a focus on technology stability, mass production capabilities, and monitoring of research and product development [4].

Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - Several companies, including Shanghai Ladder Medical Technology, are developing BCI devices aimed at treating patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis [3][4]. - Ladder Medical's BCI system has shown promising results, allowing patients to perform tasks like playing chess and racing games after just 2-3 weeks of training [3]. Group 2: Patient Recruitment and Research - The clinical cohort study led by Fudan University and Beijing Xuanwu Hospital has begun patient recruitment to validate the efficacy and safety of invasive BCI treatment [3]. - Companies like Beijing Chip Intelligence and Hangzhou Jialiang Medical have also announced plans for clinical research on BCI devices [3][4]. Group 3: Patient Impact and Demand - There is a significant demand for BCI technology, with over a thousand requests from paralyzed patients seeking participation in clinical trials [6][7]. - The development of BCI devices is seen as a beacon of hope for approximately 4 million spinal cord injury patients in China [7]. Group 4: Technological Advancements - Jialiang Medical has completed nearly 100 clinical implants for epilepsy treatment, with plans to submit data for product approval [8]. - Brain Tiger Technology has developed a next-generation wireless BCI product, which has shown capabilities in controlling complex games and smart devices [8]. Group 5: Industry Challenges and Future Outlook - Experts emphasize that while progress has been made, there is still a considerable gap between China's BCI development and that of leading global competitors [9]. - Companies are advised to focus on long-term research collaboration rather than immediate profit from BCI product sales [9].

Core Viewpoint - China's invasive brain-computer interface (BCI) devices are rapidly entering clinical trials, marking a significant advancement in the field and positioning China as the second country globally to reach this stage after the United States [1][3]. Group 1: Clinical Trials and Developments - The first prospective clinical trial of invasive BCI in China has been successfully conducted by the Chinese Academy of Sciences and Fudan University, meeting medical device registration standards [1]. - The BCI technology primarily targets patients with motor function disorders, such as spinal cord injuries and amyotrophic lateral sclerosis (ALS) [4]. - Several companies, including Shanghai Ladder Medical Technology, Beijing Chip Intelligence, and Hangzhou Jialiang Medical, are developing BCI devices and have announced clinical research plans [4]. Group 2: Patient Outcomes and Training - Initial results from the first patient implanted with an invasive BCI showed that after 2-3 weeks of training, the patient could perform tasks like playing chess and racing games, achieving a level of control similar to that of a healthy individual [3]. - The BCI system allows for two modes: outputting information from the brain to control external devices and inputting information to the brain for sensory restoration [3]. Group 3: Future Prospects and Challenges - Companies have received thousands of requests from paralyzed patients seeking participation in clinical trials, indicating a high demand for BCI technology [6][8]. - The development of BCI devices for treating epilepsy is expected to progress more rapidly, with nearly 100 patients already implanted and data being prepared for product approval [8]. - Experts emphasize the importance of focusing on the effectiveness of BCI devices for patients rather than solely on rapid commercialization [9].

Core Viewpoint - The article discusses the successful clinical trial of an invasive brain-computer interface (BCI) in China, marking a significant advancement in the field and positioning China as the second country globally to enter this stage after Neuralink. Group 1: Clinical Trial and Technology - The clinical trial was conducted by the Chinese Academy of Sciences in collaboration with Fudan University Huashan Hospital and related enterprises [2] - The trial involved a 37-year-old male who, after a severe accident leading to limb loss, can now control a computer interface using only his thoughts [27][28] - The implanted neural electrodes are the smallest and most flexible globally, with a size comparable to a coin and a flexibility exceeding that of Neuralink's products by over 100 times [4][12][10] Group 2: Technical Innovations - The team utilized semiconductor processing technology to minimize damage to brain tissue, achieving a design that is both small and soft [8][15] - The new neural electrodes have a cross-sectional area that is 1/5 to 1/7 of Neuralink's electrodes, ensuring long-term stability and functionality [10][21] - The device has a projected lifespan of 5 years, with the potential for upgrades through secondary surgeries [22][33] Group 3: Future Applications - Short-term goals include enabling users to control robotic arms for physical tasks like grasping and holding objects [6][7] - Long-term aspirations involve controlling complex physical devices, such as robotic dogs and intelligent robots, thereby expanding the boundaries of daily life [7] - The research aims to significantly improve the quality of life for individuals with complete spinal cord injuries, amputations, and amyotrophic lateral sclerosis [34]

Core Viewpoint - The article highlights the successful implementation of China's first invasive brain-computer interface (BCI) clinical trial, marking the country as the second globally to enter this phase of BCI technology [1][3]. Group 1: Clinical Trial Details - The subject of the trial is a male who lost all four limbs due to an electric shock accident. Since the implantation of the BCI device in March 2025, he has achieved functionalities such as playing chess and racing games within 2-3 weeks of training, reaching a level comparable to that of an average person using a computer touchpad [3]. - The BCI system aims to improve the quality of life for patients with spinal cord injuries and amputations through motor function replacement technology [3]. Group 2: Technological Innovations - The neural electrodes developed by the Chinese Academy of Sciences are the smallest and most flexible in the world, with a cross-sectional area only 1/5 to 1/7 of those used by Neuralink, and flexibility exceeding theirs by over a hundred times, minimizing damage to brain tissue [7]. - The BCI implant has a diameter of 26mm and a thickness of less than 6mm, making it the smallest brain-controlled implant globally, about half the size of Neuralink's product. This allows for a less invasive surgical procedure, reducing risks and recovery time [10]. Group 3: Surgical Precision - The success of the surgery relies on precise localization and implantation of the electrodes. Various brain function localization methods were employed, including functional MRI and 3D modeling, to create a detailed functional map of the patient's motor cortex, ensuring accurate implantation [11]. Group 4: Future Applications - The project team plans to enable the subject to use a robotic arm for physical tasks such as grasping and holding objects. Future developments will also include controlling complex physical devices like robotic dogs and intelligent agents to further expand the subject's capabilities [12].